BioMarin reports Q3 revenue beat but cuts full-year outlook
BioMarin Pharmaceutical (BMRN) reported Q3 revenue of $1.025B, beating estimates. EPS matched expectations at $0.23. The company lowered full-year revenue guidance by $50M and fiscal 2026 earnings guidance to $2.80-$3.10 per share, citing delays in Voxzogo orders and business development impacts. Management expects faster cost synergies from the Amicus acquisition.
How this was made
The 30-second read
Why it matters
The guidance cut reflects integration costs and slower product uptake, but cost synergies may improve margins in the near term.
Market read
The earnings and guidance update is the primary catalyst for BMRN's near‑term price action.
What to watch
Excluding the $1.87 per share impact of the Alesta acquisition shows underlying earnings may be less weak than headline guidance suggests.
Background
BioMarin is a specialty biotech focused on rare genetic diseases; recent acquisitions include Alesta and BMN 450.
Ticker impact
BioMarin posted Q3 revenue beat and cut full-year revenue and earnings guidance, lowering EPS outlook to $2.80-$3.10.
downward pressure as investors price in lower revenue and EPS forecasts
The $50 million revenue cut and EPS range reduction are material new facts that typically trigger sell‑side reactions.
Market effects
Biotech sector may see modest pullback as guidance cuts raise concerns about pipeline timing.
U.S. biotech stocks could face short‑term weakness in late‑day trading.
Limited to investors with exposure to rare‑disease therapeutics.
Counterpoint
The revenue beat and cost synergies from recent acquisitions could support a rebound if guidance is revised upward later.
Key entities
- companyBioMarin Pharmaceutical Inc.
US‑listed biotech reporting Q3 results.
